Amneal Pharmaceuticals (Amneal Pharmaceuticals) Interest Expense : $-227 Mil (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Amneal Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Amneal Pharmaceuticals's interest expense for the three months ended in Mar. 2024 was $ -66 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-227 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Amneal Pharmaceuticals's Operating Income for the three months ended in Mar. 2024 was $ 83 Mil. Amneal Pharmaceuticals's Interest Expense for the three months ended in Mar. 2024 was $ -66 Mil. Amneal Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2024 was 1.27. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Amneal Pharmaceuticals Interest Expense Historical Data

The historical data trend for Amneal Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amneal Pharmaceuticals Interest Expense Chart

Amneal Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-168.21

-146.00

-136.33

-158.38

-210.63

Amneal Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-49.32	-50.86	-50.91	-59.55	-65.70

Amneal Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-227 Mil.

Amneal Pharmaceuticals (NAS:AMRX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Amneal Pharmaceuticals's Interest Expense for the three months ended in Mar. 2024 was $-66 Mil. Its Operating Income for the three months ended in Mar. 2024 was $83 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $2,517 Mil.

Amneal Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Mar. 2024 )	/	Interest Expense (Q: Mar. 2024 )
	=	-1	*	83.235	/	-65.703
	=	1.27

The higher the ratio, the stronger the company's financial strength is.

Warning Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Amneal Pharmaceuticals Inc interest coverage is 1.19, which is low.

Amneal Pharmaceuticals (Amneal Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amneal Pharmaceuticals Inc (NAS:AMRX) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

2DT:Germany

Address

400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ, USA, 08807

Website

https://www.amneal.com

Amneal Pharmaceuticals Inc is a generic pharmaceutical manufacturer. The company's reportable segments are Generic Products, Specialty products, and AvKARE. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals, and the Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies.

Executives

Andrew S Boyer	officer: Exec VP, Comm Optns	C/O WATSON PHARMA INC, 360 MOUNT KEMBLE AVE, MORRISTOWN NJ 07960
Tpg Gp A, Llc	10 percent owner	301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Gustavo Pesquin	officer: See Remarks	4 PARK LANE, MADISON NJ 07940
Deborah M. Autor	director	C/O PARDES BIOSCIENCES, INC., 2173 SALK AVE., SUITE 250, PMB#052, CARLSBAD CA 92008
Jason B. Daly	officer: SVP, Chief Legal Officer	400 CROSSING BLVD, 3RD FLOOR, BRIDGEWATER NJ 08807
Jon Winkelried	10 percent owner	C/O GOLDMAN, SACHS & CO., 85 BROAD STREET, NEW YORK NY 10004
Gautam Patel	director	C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BLVD, BRIDGEWATER NJ 08807
Chirag K. Patel	director	C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Chintu Patel	director	C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER CA 08807
Nikita Shah	officer: SVP, Chief HR Officer	C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BLVD, BRIDGEWATER NJ 08807
Joseph Todisco	officer: SVP, Specialty Commercial	400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
John Kiely	director	C/O ZOVIO INC, 1811 E NORTHROP BLVD, CHANDLER AZ 85286
Jeffrey P. George	director	C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Shlomo Yanai	director	ONE MEADOWLANDS PLAZA, EAST RUTHERFORD NJ 07073
Paul M Meister	director	18 SHIP ROCK ROAD, NORTH HAMPTON NH 03862